Study of Prognostic and Predictive Markers for Treatment Response in Adults With Bile Duct Cancer in the ACABi PRONOBIL Cohort

What this Trial Is About

Researchers are investigating bile duct cancers, a rare group of tumors with generally poor outcomes. This study aims to identify markers that can predict how patients respond to treatments like surgery, chemotherapy, targeted therapy, and local treatments, as well as to evaluate the effectiveness and tolerance of these treatments in current practice. The study includes both retrospective and prospective parts, spanning diagnoses from 2003 to 2030, with a focus on improving treatment decisions for patients. The study is a multi-center cohort observing patients diagnosed between 2003 and 2030. It includes those with intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder adenocarcinoma, excluding ampullomas. Patients are followed for up to 10 years from diagnosis. Data collection involves reviewing treatments such as surgery and chemotherapy, as well as their outcomes and side effects. Past patient data are used for retrospective parts, while new patients diagnosed after 2021 are followed prospectively. Participants will have their medical records reviewed for treatment responses, survival rates, complications, and side effects over a long period. Outcomes measured include overall survival, disease-free survival, progression-free survival, response rates, and postoperative mortality. Genetic studies may also be part of the research with consent. The study allows data use for educational purposes with proper authorization. Participation spans up to 10 years from diagnosis, with follow-up continuing until death or study end.

Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study